Publications
75 results found
Seckl MJ, Roy R, Mauri F, et al., 2013, FGF-2 INDUCES CHEMORESISTANCE IN MODEL AND LUNG CANCER CELLS THROUGH S6K2/HNRNPA1-MEDIATED ENHANCED TRANSLATION OF ANTI-APOPTOTIC PROTEINS, JOURNAL OF THORACIC ONCOLOGY, Vol: 8, Pages: S1037-S1038, ISSN: 1556-0864
Kaliszczak M, Pardo OE, Seckl MJ, et al., 2013, HDAC6 inhibitor C1A abrogates the recruitment of the autophagic machinery and synergizes with proteasome, src kinase, and PI3K-mTOR inhibition., MOLECULAR CANCER THERAPEUTICS, Vol: 12, ISSN: 1535-7163
Tang H, Li H, Wang Y, et al., 2013, Combined preparation and application of combined preparation in preparing non-small-cell lung carcinoma drug, CN103330940A
The invention discloses a combined preparation and an application of the combined preparation in preparing a non-small-cell lung carcinoma drug. An EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and a preparation for increasing a concentration of glutathione (GSH) in lung carcinoma cells are administered simultaneously or successively. According to the combined preparation and the application, through a systemic research, the GSH plays an important role in resisting the EGFR tyrosine kinase inhibitor to an EGFR T790M mutation non-small-cell lung carcinoma, so that drug resisting cells are sensitive to treatment of the EGFR tyrosine kinase inhibitor again by utilizing a mode of increasing the concentration of the GSH in the lung carcinoma cells; and a cell experiment and an animal experiment prove that the method is safe and effective, can effectively kill the lung carcinoma cells, and can inhibit proliferation of the lung carcinoma cells.
Lara R, Seckl MJ, Pardo OE, 2013, The p90 RSK Family Members: Common Functions and Isoform Specificity, CANCER RESEARCH, Vol: 73, Pages: 5301-5308, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 90
Pardo OE, Seckl MJ, 2013, S6K2: The Neglected S6 Kinase Family Member., Frontiers in Oncology, Vol: 3, ISSN: 2234-943X
S6 kinase 2 (S6K2) is a member of the AGC kinases super-family. Its closest homolog, S6K1, has been extensively studied along the years. However, due to the belief in the community that the high degree of identity between these two isoforms would translate in essentially identical biological functions, S6K2 has been largely neglected. Nevertheless, recent research has clearly highlighted that these two proteins significantly differ in their roles in vitro as well as in vivo. These findings are significant to our understanding of S6 kinase signaling and the development of therapeutic strategies for several diseases including cancer. Here, we will focus on S6K2 and review the protein-protein interactions and specific substrates that determine the selective functions of this kinase.
Liwak U, Thakor N, Jordan LE, et al., 2012, Tumor Suppressor PDCD4 Represses Internal Ribosome Entry Site-Mediated Translation of Antiapoptotic Proteins and Is Regulated by S6 Kinase 2, MOLECULAR AND CELLULAR BIOLOGY, Vol: 32, Pages: 1818-1829, ISSN: 0270-7306
- Author Web Link
- Cite
- Citations: 72
Lara R, Mauri F, Gray C, et al., 2011, An siRNA screen identifies RSK1 as a key regulator of lung cancer metastasis., Oncogene, Vol: 30, Pages: 3513-3521
We performed a kinome-wide siRNA screen and identified 70 kinases altering cell migration in A549 lung cancer cells. In particular, ribosomal S6 kinase 1 (RSK1) silencing increased, whereas RSK2 and RSK4 downregulation inhibited cell motility. In a secondary collagen-based three-dimensional invasion screen, 38 of our hits cross-validated, including RSK1 and RSK4. In two further lung cancer cell lines, RSK1 but not RSK4 silencing showed identical modulation of cell motility. We therefore selected RSK1 for further investigation. Bioinformatic analysis followed by co-immunoprecipitation-based validation revealed that the actin regulators VASP and Mena interact with RSK1. Moreover, RSK1 phosphorylated VASP on T278, a site regulating its binding to actin. In addition, silencing of RSK1 enhanced the metastatic potential of these cells in vivo using a zebrafish model. Finally, we investigated the relevance of this finding in human lung cancer samples. In isogenically matched tissue, RSK1 was reduced in metastatic versus primary lung cancer lesions. Moreover, patients with RSK1-negative lung tumours showed increased number of metastases. Our results suggest that the findings of our high-throughput in vitro screen can reliably identify relevant clinical targets and as a proof of principle, RSK1 may provide a biomarker for metastasis in lung cancer patients
Lara R, Mauri FA, Taylor H, et al., 2011, An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis, ONCOGENE, Vol: 30, Pages: 3513-3521, ISSN: 0950-9232
- Author Web Link
- Cite
- Citations: 73
Rupniewska E, Mauri F, Watling D, et al., 2011, ROLE OF SRC FAMILY KINASES IN NSCLC: AUTOPHAGY INHIBITORS POTENTIATE KILLING EFFECTS OF DASATINIB, JOURNAL OF THORACIC ONCOLOGY, Vol: 6, Pages: S744-S745, ISSN: 1556-0864
Lara R, Mauri F, Taylor H, et al., 2011, IDENTIFICATION OF RSK1 AS A KEY MODULATOR OF LUNG CANCER METASTASIS, JOURNAL OF THORACIC ONCOLOGY, Vol: 6, Pages: S514-S515, ISSN: 1556-0864
De Laurentiis A, Pardo OE, Palamidessi A, et al., 2011, The catalytic class I<sub>A</sub> PI3K isoforms play divergent roles in breast cancer cell migration, CELLULAR SIGNALLING, Vol: 23, Pages: 529-541, ISSN: 0898-6568
- Author Web Link
- Cite
- Citations: 9
Rupniewska E, Watling D, Mauri FA, et al., 2010, Src family kinases in lung cancer, 21st Meeting of the European-Association-for-Cancer-Research, Publisher: Elsevier, Pages: 95-95, ISSN: 1878-1217
Goh ETH, Pardo OE, Michael N, et al., 2010, Involvement of Heterogeneous Ribonucleoprotein F in the Regulation of Cell Proliferation via the Mammalian Target of Rapamycin/S6 Kinase 2 Pathway, JOURNAL OF BIOLOGICAL CHEMISTRY, Vol: 285, Pages: 17065-17076
- Author Web Link
- Cite
- Citations: 42
Pardo OE, Latigo J, Jeffery RE, et al., 2009, The Fibroblast Growth Factor Receptor Inhibitor PD173074 Blocks Small Cell Lung Cancer Growth <i>In vitro</i> and <i>In vivo</i>, CANCER RESEARCH, Vol: 69, Pages: 8645-8651, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 138
Seckl MJ, Pardo OE, Aboagye EO, et al., 2009, The FGF receptor (FGFR) inhibitor PD0173074 blocks SCLC growth in vitro and in vivo, JOURNAL OF THORACIC ONCOLOGY, Vol: 4, Pages: S385-S385, ISSN: 1556-0864
Seckl M, Pardo OE, Lara R, et al., 2009, RNAi library screen reveals RSK1 as a key regulator of lung cancer metastasis, JOURNAL OF THORACIC ONCOLOGY, Vol: 4, Pages: S559-S560, ISSN: 1556-0864
Lara R, Mauri F, Gray C, et al., 2009, An siRNA screen identifies RSK family members as key regulator of lung cancer metastasis, CANCER RESEARCH, Vol: 69, ISSN: 0008-5472
Marinov M, Ziogas A, Pardo OE, et al., 2009, AKT/mTOR Pathway Activation and BCL-2 Family Proteins Modulate the Sensitivity of Human Small Cell Lung Cancer Cells to RAD001, CLINICAL CANCER RESEARCH, Vol: 15, Pages: 1277-1287, ISSN: 1078-0432
- Author Web Link
- Cite
- Citations: 79
Yuan M, Tomlinson V, Lara R, et al., 2008, Yes-associated protein (YAP) functions as a tumor suppressor in breast, CELL DEATH AND DIFFERENTIATION, Vol: 15, Pages: 1752-1759, ISSN: 1350-9047
- Author Web Link
- Cite
- Citations: 260
Pardo O, Downward J, Seckl MJ, 2008, Protein Complex involving PKCepsilon, BRaf and S6K2 and uses, WO 2008/078057 A1
Marinov M, Ziogas A, Pardo OE, et al., 2007, Akt/mTOR pathway activation and Bcl-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001 (Everolimus), MOLECULAR CANCER THERAPEUTICS, Vol: 6, Pages: 3409S-3409S, ISSN: 1535-7163
Charles Swanton, Michela Marani, Olivier Pardo, et al., 2007, Regulators of Mitotic Arrest and Ceramide Metabolism Are Determinants of Sensitivity to Paclitaxel and Other Chemotherapeutic Drugs, Cancer Cell, Vol: 11, Pages: 498-512
Katso RM, Pardo OE, Palamidessi A, et al., 2006, Phosphoinositide 3-kinase C2β regulates cytoskeletal organization and cell migration via Rac-dependent mechanism, MOLECULAR BIOLOGY OF THE CELL, Vol: 17, Pages: 3729-3744, ISSN: 1059-1524
- Author Web Link
- Cite
- Citations: 67
Pardo OE, Wellbrock C, Khanzada UK, et al., 2006, FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCε, B-Raf and S6K2, EMBO JOURNAL, Vol: 25, Pages: 3078-3088, ISSN: 0261-4189
- Author Web Link
- Cite
- Citations: 150
Khanzada UK, Pardo OE, Meier C, et al., 2006, Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling, ONCOGENE, Vol: 25, Pages: 877-887, ISSN: 0950-9232
- Author Web Link
- Cite
- Citations: 97
Michl P, Ramjaun AR, Pardo OE, et al., 2005, CUTL1 is a target of TGFβ signaling that enhances cancer cell motility and invasiveness, CANCER CELL, Vol: 7, Pages: 521-532, ISSN: 1535-6108
- Author Web Link
- Cite
- Citations: 133
Pardo OE, Lesay A, Arcaro A, et al., 2004, Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells (vol 23, pg 7600, 2003), MOLECULAR AND CELLULAR BIOLOGY, Vol: 24, Pages: 6887-6887, ISSN: 0270-7306
- Author Web Link
- Cite
- Citations: 2
Pardo OE, Lesay A, Arcaro A, et al., 2003, Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells, MOLECULAR AND CELLULAR BIOLOGY, Vol: 23, Pages: 7600-7610, ISSN: 0270-7306
- Author Web Link
- Cite
- Citations: 91
Pardo OE, Arcaro A, Seckl MJ, 2002, Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells, BRITISH JOURNAL OF CANCER, Vol: 86, Pages: S120-S120, ISSN: 0007-0920
Pardo OE, Arcaro A, Salerno G, et al., 2002, Fibroblast growth factor-2 induces translational regulation of Bcl-X<sub>L</sub> and Bcl-2 via a MEK-dependent pathway -: Correlation with resistance to etoposide-induced apoptosis, JOURNAL OF BIOLOGICAL CHEMISTRY, Vol: 277, Pages: 12040-12046, ISSN: 0021-9258
- Author Web Link
- Cite
- Citations: 134
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.